Long-term safety and tolerability of flutamide for the treatment of hirsutism

Fertility and Sterility

Volumn 91, Issue 4, 2009, Pages 1183-1188

  Castelo Branco, Camil ^a   Moyano, Dolores ^a   Gómez, Olga ^a   Balasch, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

adverse effects; flutamide; hirsutism; hyperandrogenism; Safety; tolerability

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; FLUTAMIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; FLATULENCE; FOLLOW UP; HEADACHE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; LABORATORY TEST; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; FLUTAMIDE; FOLLOW-UP STUDIES; HIRSUTISM; HUMANS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62949130858     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.01.046     Document Type: Article

References (37)

1. Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., and Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85 (2000) 2434-2438
2. Stankiewicz M., and Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guide. Drugs 66 (2006) 903-912
3. Batukan C., Muderris I.I., Ozcelik B., and Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 23 (2007) 38-44
4. Moghetti P., and Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab 20 (2006) 221-234
5. Castelo-Branco C., Martinez de Osaba M.J., Pons F., and Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 46 (1997) 437-440
6. Harwood K., Vuguin P., and Dimartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 68 (2007) 209-217
7. Setji T.L., and Brown A.J. Polycystic ovary syndrome: diagnosis and treatment. Am J Med 120 (2007) 128-132
8. Castelo-Branco C., Martinez de Osaba M.J., Martinez S., and Fortuny A. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Metabolism 45 (1996) 24-27
9. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol (2007) Sep 4 [Epub ahead of print]. Last accessed: February 5, 2008
10. Bhathena R.K. Therapeutic options in the polycystic ovary syndrome. J Obstet Gynaecol 27 (2007) 123-129
11. Ibanez L., and de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 12 (2006) 243-252
12. Couzinet B., Pholsena M., Young J., and Schaison G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol (Oxf) 39 (1993) 157-162
13. Taner C., Inal M., Basogul O., Onoglu A., Karanfil C., Tinar S., et al. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet Invest 54 (2002) 105-108
14. Ibanez L., Lopez-Bermejo A., del Rio L., Enriquez G., Valls C., and de Zegher F. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab 92 (2007) 1710-1714
15. Muderris I.I., Bayram F., and Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 14 (2000) 38-41
16. Famularo G., De Simone C., Minisola G., and Nicotra G.C. Flutamide-associated acute liver failure. Ann Ital Med Int 18 (2003) 250-253
17. Garcia Cortes M., Andrade R.J., Lucena M.I., Sanchez Martinez H., Fernandez M.C., Ferrer T., et al. Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig 93 (2001) 423-432
18. Ruiz-Rebollo M., Atienza-Sanchez R., and Lopez-Garcia E. [Hirsutism, flutamide and hepatotoxicity]. Gastroenterol Hepatol 24 (2001) 218
19. Roman Llorente F.J., Alvarez Navascues C., and Suarez Gonzalez A. Gonzalez Bernal AC. [Toxic hepatitis caused by flutamide and hirsutism]. Gastroenterol Hepatol 23 (2000) 258
20. Andrade R.J., Lucena M.I., Fernandez M.C., Suarez F., Montero J.L., Fraga E., et al. Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet 353 (1999) 983
21. Wysowski D.K., and Fourcroy J.L. Flutamide hepatotoxicity. J Urol 155 (1996) 209-212
22. Rosenfield R.L. Clinical practice. Hirsutism. N Engl J Med 353 (2005) 2578-2588
23. Muderris I.I., Bayram F., and Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 73 (2000) 984-987
24. Calaf J., Lopez E., Millet A., Alcaniz J., Fortuny A., Vidal O., et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 92 (2007) 3446-3452
25. Cusan L., Dupont A., Gomez J.L., Tremblay R.R., and Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 61 (1994) 281-287
26. Moghetti P., Castello R., Negri C., Tosi F., Magnani C.M., Fontanarosa M.C., et al. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril 64 (1995) 511-517
27. Balasch J., Fabregues F., Penarrubia J., Carmona F., Casamitjana R., Creus M., et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 21 (2006) 1884-1893
28. Zouboulis C.C., Chen W.C., Thornton M.J., Qin K., and Rosenfield R. Sexual hormones in human skin. Horm Metab Res 39 (2007) 85-95
29. Moghetti P. Use of antiandrogens as therapy for women with polycystic ovary syndrome. Fertil Steril 86 Suppl 1 (2006) S30-S31
30. Erenus M., Yucelten D., Gurbuz O., Durmusoglu F., and Pekin S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril 66 (1996) 216-219
31. Zouboulis C.C., and Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 206 (2003) 37-53
32. Nguyen T.V., Yao M., and Pike C.J. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection. Endocrinology 148 (2007) 2936-2943
33. Adkins-Regan E., and Garcia M. Effect of flutamide (an antiandrogen) and diethylstilbestrol on the reproductive behavior of Japanese quail. Physiol Behav 36 (1986) 419-425
34. Carmina E. Anti-androgens for the treatment of hirsutism. Expert Opin Investig Drugs 11 (2002) 357-363
35. Kackar R.R., and Desai H.G. Hepatic failure with flutamide. Indian J Gastroenterol 22 (2003) 149-150
36. Thole Z., Manso G., Salgueiro E., Revuelta P., and Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 73 (2004) 289-295
37. Albertsen P.C., Aaronson N.K., Muller M.J., Keller S.D., and Ware Jr. J.E. Health-related quality of life among patients with metastatic prostate cancer. Urology 49 (1997) 207-216 discussion 16-7